EUVIMEDEUVIMED entdecken
Crossref

Management and Treatment of Neurofibromatosis Type I

Andrew Ferrier

Canadian Dermatology Today · 2024

DOI: 10.58931/cdt.2024.53123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Dermatology Today, 2024. Verfasst von Andrew Ferrier. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurofibromatosis type 1 (NF1) is an autosomal dominant tumour suppressor syndrome associated with benign and malignant tumours, predominantly affecting the skin and nervous system. NF1, the most prevalent neurocutaneous syndrome, and the focus of this review, has a frequency of ~ 1/1,900-1/3,500 people worldwide. Disease manifestations can present at birth and emerge with age, negatively impacting multiple clinical domains and imparting a profound impact on a patient’s quality of life and life expectancy. Given its progressive nature and marked clinical variability, NF1 warrants a multidisciplinary approach to management and treatment.

Zitieren

APA

Ferrier, A. (2024). Management and Treatment of Neurofibromatosis Type I. Canadian Dermatology Today. https://doi.org/10.58931/cdt.2024.53123

Vancouver

Ferrier A. Management and Treatment of Neurofibromatosis Type I. Canadian Dermatology Today. 2024. doi:10.58931/cdt.2024.53123

BibTeX
@article{Ferrier2024,
  author = {Ferrier, Andrew},
  title = {Management and Treatment of Neurofibromatosis Type I},
  journal = {Canadian Dermatology Today},
  year = {2024},
  doi = {10.58931/cdt.2024.53123}
}
Kostenlos starten →